Edition:
United States

Jiangsu Hengrui Medicine Co Ltd (600276.SS)

600276.SS on Shanghai Stock Exchange

83.85CNY
2:49am EDT
Change (% chg)

¥0.08 (+0.10%)
Prev Close
¥83.77
Open
¥83.00
Day's High
¥85.19
Day's Low
¥81.02
Volume
14,969,144
Avg. Vol
12,099,296
52-wk High
¥89.23
52-wk Low
¥44.04

Latest Key Developments (Source: Significant Developments)

Jiangsu Hengrui Says Q1 Net Profit Up 16.95 Percent Y/Y
Thursday, 26 Apr 2018 04:21am EDT 

April 26 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::SAYS Q1 NET PROFIT UP 16.95 PERCENT Y/Y.  Full Article

Jiangsu Hengrui Medicine unit passes U.S. FDA approval
Thursday, 1 Mar 2018 08:31pm EST 

March 2(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says co's unit Shanghai Hengrui Pharmaceutical Co Ltd received FDA approval for desflurane for inhalation (product) from U.S. Food and Drug Administration.Says unit will be able to sell the product in U.S. after receiving the FDA approval.  Full Article

Jiangsu Hengrui Medicine receives GMP certificate
Wednesday, 28 Feb 2018 05:23am EST 

Feb 28 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS> ::* Says it received goods manufacture practice (GMP) certificate from Health and Youth Care Inspectorate.* Certificate issued iodixanol injection, oxaliplatin for injection and caspofungin acetate for injection as well as Letrozole Tablets manufactured by the company and the valid period is until Sep. 2020.  Full Article

TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies
Monday, 8 Jan 2018 07:30am EST 

Jan 8 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES.TG THERAPEUTICS INC - ‍ UNDER TERMS, HENGRUI WILL RECEIVE AN UP-FRONT LICENSING FEE AND NEAR-TERM MILESTONES, PAYABLE IN TG COMMON STOCK​.TG THERAPEUTICS INC - ‍HENGRUI IS ELIGIBLE TO RECEIVE COLLABORATION AND LICENSING PAYMENTS OF ABOUT $350 MILLION, IN ADDITION TO ROYALTIES ON FUTURE SALES​.  Full Article

Jiangsu Hengrui Medicine says license agreement on JAK1 inhibitor SHR0302 with U.S.-based firm Arcutis
Friday, 5 Jan 2018 02:40am EST 

Jan 5(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says co signs license agreement with U.S.-based firm Arcutis regarding JAK1 inhibitor SHR0302 .Says co grants Arcutis an exclusive right to develop and sell JAK1 inhibitor SHR0302 in United States of America, European Union and Japan.Says co will receive upfront and milestones payment of up to $223 million and sales commissions from Arcutis.  Full Article

Jiangsu Hengrui Medicine passes U.S. FDA approval
Wednesday, 29 Nov 2017 05:44am EST 

Nov 29(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it received FDA approval for Dexmedetomidine Hydrochloride Injection from U.S. Food and Drug Administration.Company will be able to sell its Dexmedetomidine Hydrochloride Injection in the United States after receiving the FDA approval.  Full Article

Jiangsu Hengrui Medicine gets approval for clinical trials of drugs
Tuesday, 7 Nov 2017 03:32am EST 

Nov 7 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it gets clinical trials approval for its drug named Seebri® Breezhaler® from China Food and Drug Administration.  Full Article

Jiangsu Hengrui Medicine's 9-month net profit up 20.7 pct y/y
Wednesday, 18 Oct 2017 06:17am EDT 

Oct 18 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says 9-month net profit up 20.7 percent y/y at 2.3 billion yuan ($347.33 million).  Full Article

Jiangsu Hengrui Medicine passes FDA approval
Tuesday, 5 Sep 2017 03:05am EDT 

Sept 5(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it received approval for its cisatracurium besilate injection from U.S Food and Drug Administration .Says the company will be able to sell its cisatracurium besilate injection in the United States after receiving the FDA approval.  Full Article

Jiangsu Hengrui Medicine's H1 net profit up 19.7 pct y/y
Tuesday, 29 Aug 2017 03:40am EDT 

Aug 29 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says H1 net profit up 19.7 percent y/y at 1.6 billion yuan ($242.26 million).  Full Article

BRIEF-Jiangsu Hengrui Medicine unit passes U.S. FDA approval

* Says co's unit Shanghai Hengrui Pharmaceutical Co Ltd received FDA approval for desflurane for inhalation (product) from U.S. Food and Drug Administration